We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

By LabMedica International staff writers
Posted on 06 May 2025

Speed and accuracy are essential when diagnosing diseases. More...

Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures, often resulting in several days of waiting before targeted treatment can begin. Researchers have now developed a groundbreaking method that can identify bacteria with unprecedented speed, reducing the waiting time from several days to just a few minutes.

The innovative approach, developed by researchers at Technical University of Munich (TUM, Munich, Germany) and Imperial College London (London, UK) uses mass spectrometry to detect specific metabolic products of bacteria directly from tissue and stool samples. Central to this process is a database that currently includes 232 medically relevant bacterial species and their associated metabolic products. From this database, biomarkers are extracted to allow for the direct identification of specific bacteria.

The new method is capable of identifying bacteria responsible for a variety of serious conditions, including stomach cancer, pneumonia, meningitis, preterm birth, gonorrhea, and sepsis. To ensure that this method becomes a regular tool in clinical settings, the biomarker database needs to be expanded. The researchers note that over 1,400 bacterial pathogens are known, and their specific metabolic products need to be identified and added to the database. The team also sees significant potential for this method in personalized medicine, where treatments can be tailored precisely to individual patients based on the specific bacteria detected.

"Our innovative approach is not to look directly for the pathogenic bacteria, but only for their metabolic products. This allows us to detect them indirectly, but much more quickly," said first author Wei Chen.

"This is one of the most important future topics in biotechnology and medicine. Targeted interventions can dramatically improve the chances of successful treatment. As analysts, we develop modern tools and methods for doctors to do this," added Prof. Nicole Strittmatter.

Related Links:
TUM 
Imperial College London 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.